**Core tip:** This study investigated the associations between single nucleotide polymorphisms of interleukin-21 (*IL-21*) gene (rs907715, rs2221903 and rs12508721) and gastric precancerous lesions in a Chinese population. The results showed an association between *IL-21* rs907715 polymorphism and gastric precancerous lesions. *IL-21* rs907715 genotype CC and C frequencies were higher in patients with gastric precancerous lesions than in the controls. Single nucleotide polymorphism rs907715 increased in CC and C genotypes were associated with intestinal metaplasia patients when examined separately. These findings may help clarify the etiology of gastric cancer.

INTRODUCTION
============

Gastric cancer (GC) is the fifth most common malignancy worldwide, and ranks second in incidence and mortality among all malignancies in China\[[@B1],[@B2]\]. GC is considered to be a multistep progression from non-atrophic gastritis (NAG), atrophic gastritis (AG), intestinal metaplasia (IM), dysplasia, to gastric adenocarcinoma\[[@B3]\]. The worldwide prevalences of AG and IM were 33% and 25% respectively\[[@B4]\]. As the specific recognizable stages of the precancerous cascade\[[@B5]\], gastric precancerous lesions can increase the risk of GC\[[@B6],[@B7]\], so clarifying the etiology of gastric precancerous lesions is of great significance in preventing the development of GC\[[@B8]\]. Multiple factors contribute to the occurrence and development of gastric precancerous lesions, including environmental factors, such as *Helicobacter pylori* infection\[[@B9],[@B10]\], high salt intake\[[@B11],[@B12]\], alcohol consumption\[[@B12]\], and smoking status\[[@B13]\]. Some studies have explored genetic risk factors for precancerous lesions such as *interleukin (IL)-1*, *IL-8*, *IL-10*, and *IL-22*\[[@B14]-[@B18]\], but less attention has been given to *IL-21*.

*IL-21* is an immune modulatory cytokine produced mainly by activated CD4^+^T cells and natural killer (NK) cells, and has multiple effects on innate and adaptive immune responses\[[@B19]\]. The activity of *IL-21* is mediated via binding to a compound receptor consisting of *IL-21R* and γ chain\[[@B20],[@B21]\], and the biological functions of *IL-21* include promoting T-cell proliferation, stimulating B-cell differentiation, and enhancing NK-cell activation\[[@B22],[@B23]\]. *IL-21* plays important roles in inflammatory, antiviral, and antitumor responses\[[@B24]\]. Single nucleotide polymorphisms (SNPs) of the *IL-21* gene can change the expression level of mRNA, resulting in a change in protein expression or autoantibody production\[[@B25]\]. SNPs of *IL-21* have been associated with various diseases of the immune system including systemic lupus erythematosus\[[@B26]\], Graves' disease\[[@B27]\], rheumatoid arthritis\[[@B28]\], and hepatitis B virus (HBV) infection\[[@B29]\]. Several SNPs of *IL-21* (rs907715, rs2221903 and rs12508721) have also been associated with the susceptibility to cancer\[[@B30]-[@B33]\]. For example, SNPs rs907715 and rs2221903 reduce the susceptibility to non-small cell lung cancer\[[@B30]\], and SNP rs12508721 is related to thyroid cancer\[[@B31]\], breast cancer\[[@B32]\] and HBV-related hepatocellular carcinoma\[[@B33]\]. Previous studies have found that *IL-21* may be associated with the risk of gastric precancerous lesions\[[@B34],[@B35]\]. However, no studies have examined the possible role of *IL-21* SNPs (rs907715, rs2221903 and rs12508721) in gastric precancerous lesions. Therefore, the present study explored associations between SNPs of *IL-21* (rs907715, rs2221903 and rs12508721) and risk of gastric precancerous lesions in a northwestern Chinese population.

MATERIALS AND METHODS
=====================

Subjects
--------

This study was conducted from May 2014 to December 2016 in hospitals from three cities (Yulin, North; Xi\'an, Middle; Hanzhong, South) in Shaanxi Province, China (Figure [1](#F1){ref-type="fig"}). Men and women with gastrointestinal symptoms requiring upper endoscopy examination were screened for study eligibility. Individuals diagnosed with GC were excluded, while a total of 1674 subjects who had undergone upper gastrointestinal endoscopy, completed pathological and 24-hour urine testing were included. The medical records of all subjects were reviewed retrospectively.

![Location map of three selected cities in Shaanxi province, China.](WJGO-12-289-g001){#F1}

Of the eligible and willing subjects, 588 with NAG, AG, or IM (cases) and 290 without any diagnosis of gastric diseases or *H. pylori* infection (controls) were enrolled. This study was performed in accordance with the Declaration of Helsinki of the World Medical Association and was approved by the Institutional Review Board of Xi'an Jiaotong University Health Science Center. Informed consent was obtained from all subjects.

Data measurements and collection
--------------------------------

Demographic information was obtained from subjects' medical records including age, gender, smoking status, drinking status, height, and weight. For smoking status and drinking status, subjects were dichotomized as "yes" or "no". Body mass index was calculated as weight in kilograms divided by height in meters squared.

Daily salt intake was determined by 24-hour urine sodium excretion and was dichotomized as "high salt" and "non-high salt" according to the median of the controls (representing the general population). Subjects were asked to excrete and discard their first urine at 7 a.m. and to collect all urine over the following 24-hours, including the next day first urine at 7 a.m. Total volumes of the collection were measured. Urinary sodium levels were measured by the ion selective electrode method using by Olympus AU 680 autoanalyser.

In this study, NAG, AG, and IM were diagnosed by endoscopic findings and based on updated Sydney system criteria\[[@B36]\] and Atrophy Club criteria\[[@B37]\]. The serum *H. pylori* IgG antibody test was performed by an enzyme-linked immunosorbent assay on the same day of endoscopy. IgG values ≥ 10 U/mL were considered as "*H. pylori* infection" and \< 10 U/mL as negative results\[[@B38]\].

Genotyping
----------

Three SNPs (rs907715, rs2221903, and rs12508721) of IL-21 were genotyped in cases and controls. Genomic DNA was extracted from 5 mL peripheral blood samples using the Blood DNA Kit (Tiangen, Beijing, China), and stored at -80°C until subsequent assay. SNPs were genotyped using the polymerase chain reaction (PCR)--ligase detection reaction method using assay-on-demand probes and primers: C_8949748_10 for rs907715, C_16167441_10 for rs2221903, C_1597500_10 for rs12508721. The forward and reverse primers are shown in Table [1](#T1){ref-type="table"}. All primers were designed using the Primer3 program (<http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_>[www.cgi](www.cgi)). The reaction was performed in a total volume of 20 µL, containing genomic DNA (1 µL), buffer (2 µL), MgCl~2~ (0.6 µL), dNTPs (2 µL), *Taq* polymerase (0.2 µL), 2 µL of each primer, and 12.2 µL ddH~2~O. PCR conditions were as follows: denaturation at 95 °C for 2 min, 94 °C for 30 s; annealing at 56 °C for 90 s; extension at 40 cycles of 65 °C for 30 s, and a final extension at 65 °C for 10 min. Following amplification, PCR products were submitted for DNA sequencing.

###### 

Probe primary information for genotyping *interleukin-21* gene polymorphisms

  **Primer**   **Type**                        **Primer sequences, 5′→3′**
  ------------ ------------------------------- ------------------------------
  rs907715     F                               5′-ATAGATGAGGAAAGTGAGATC-3′
  R            5′- CTTTGCTTATTTGATATATTCC-3′   
  rs2221903    F                               5′-GGACCACATATTGCCAG ACAC-3′
  R            5′-GACACTGACGCCCATATTGAT-3′     
  rs12508721   F                               5′-ATGGGACTAAAGT CAAGGTG-3′
  R            5′-AGATGGCTTCTAGAGTCTGG-3′      

Trizol was used for extraction of mRNA from six intestinal epithelium tissues according to the manufacturer's instructions. Quantification of mRNA of rs907715 was performed using BioEasy SYBR Green Real Time PCR Kit in a 20 μL reaction volume, containing SYBR Green Master Mix (10 μL), PCR Forward Primer (0.8 μL), cDNA (2 μL), ROX (0.4 μL) and nuclease-free water (6 μL). Extension was performed under the following conditions: Initial denaturation at 95 °C for 5 min, followed by 40 cycles at 95 °C for 5 s and 60 °C for 34 s. All reactions were performed in duplicate. Using the 2^−ΔΔCt^ method\[[@B39]\] to calculate the relative mRNA expression levels.

Statistical analysis
--------------------

Descriptive statistics were used to describe demographic characteristics of all subjects in our study. Genotype frequencies of three SNPs (rs907715, rs2221903, and rs12508721) were obtained by statistical description, and Hardy-Weinberg equilibrium was analyzed using the chi-squared goodness of fit test. Logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) of gastric precancerous lesions for genotype, controlling for demographic and lifestyle factors (age, gender, body mass index, drinking status, smoking status, daily salt intake and region). Distribution normality of *IL-21* mRNA expression was assessed using the Kolmogorov--Smirnov test, differences among three genotypes were measured using an independent sample Student's *t*-test. All analyses were performed with SPSS 22.0 software (IBM, Chicago, IL, United States). A two-tailed *P* \< 0.05 was considered statistically significant.

RESULTS
=======

Demographic and lifestyle associations
--------------------------------------

A total of 1674 subjects were included in the study, aged 26 to 88 with a mean age of 49.8 (SD = 11.4). The incidences of NAG, AG, and IM were 6.9%, 6.3%. and 21.9%, respectively (Table [2](#T2){ref-type="table"}). The NAG incidence in the south region was higher than that in other two regions, while AG and IM incidences in middle region were higher than those in other two regions.

###### 

Demographic and lifestyle characteristics of participants in different regions

  **Characteristic**      **North**   **Middle**    **South**   **Total**                                
  ----------------------- ----------- ------------- ----------- ------------- ----- ------------- ------ -------------
  Gender                                                                                                 
  Female                  464         62.5          128         26.2          136   30.6          728    43.5
  Male                    278         37.5          360         73.8          308   69.4          946    56.5
  BMI                     742         20.0 ± 3.2    488         20.6 ± 2.8    444   20.3 ± 2.2    1674   20.6 ± 2.0
  Age in yr               742         52.9 ± 15.1   488         46.3 ± 12.8   444   47.5 ± 15.0   1674   49.8 ± 11.4
  \< 40                   110         36.2 ± 5.4    174         36.9 ± 5.2    76    36.7 ± 3.9    360    35.8 ± 2.9
  40-49                   220         45.1 ± 4.2    202         44.7 ± 4.5    288   44.8 ± 2.1    710    45.5 ± 2.0
  50-59                   150         54.6 ± 6.1    28          51.8 ± 1.9    8     54.4 ± 2.5    186    54.2 ± 2.0
  ≥ 60                    262         66.1 ± 5.0    84          68.3 ± 11.1   72    77.0 ± 10.4   418    68.0 ± 8.4
  Lifestyle                                                                                              
  High salt               230         31.0          112         23.0          56    12.6          398    23.8
  Smoking                 314         42.3          142         29.1          318   71.6          774    46.2
  Drinking                286         38.5          116         23.8          184   41.4          586    35.0
  Clinical diagnosis                                                                                     
  *H. pylori* infection   512         69.0          296         60.7          360   81.1          1168   69.8
  NAG                                                                                                    
  None                    700         94.3          470         96.3          388   87.4          1558   93.1
  Mild                    23          3.1           10          2.1           35    7.9           68     4.1
  Moderate                16          2.2           6           1.2           17    3.8           39     2.3
  Severe                  3           0.4           2           0.4           4     0.9           9      0.5
  AG                                                                                                     
  None                    722         97.3          438         89.8          408   91.9          1568   93.7
  Mild                    13          1.8           33          6.8           23    5.1           69     4.1
  Moderate                6           0.8           14          2.8           10    2.3           30     1.8
  Severe                  1           0.1           3           0.6           3     0.7           7      0.4
  IM                                                                                                     
  None                    612         82.5          328         67.2          368   82.9          1308   78.1
  Mild                    87          11.7          104         21.3          48    10.9          239    14.3
  Moderate                34          4.6           45          9.2           23    5.1           102    6.1
  Severe                  9           1.2           11          2.3           5     1.1           25     1.5

Data presented as (mean ± standard deviation). BMI: Body mass index; *H. pylori*: *Helicobacter pylori*; NAG: Non-atrophic gastritis; AG: Atrophic gastritis; IM: Intestinal metaplasia.

High salt intake was associated with an increased risk of NAG (OR = 2.58, 95%CI: 1.21-4.88, *P* = 0.011) (Table [3](#T3){ref-type="table"}); *H. pylori* infection was correlated with decreased risk of AG (OR = 0.39, 95% 95%CI: 0.65-0.99, *P* = 0.041); and smoking was related to increased risk of NAG (OR = 2.15, 95%CI: 1.19-4.44, *P* = 0.015) and IM (OR = 1.97, 95%CI: 1.40-2.58, *P* = 0.005). Compared with the south region, subjects in the middle region had a lower risk of NAG (OR = 0.33, 95%CI: 0.28-0.51, *P* = 0.009) and a higher risk of IM (OR = 2.95, 95%CI: 1.45-4.33, *P* = 0.007); subjects in the north region had a lower risk of AG (OR = 0.33, 95%CI: 0.21-0.83, *P* = 0.010).

###### 

Association between risk factors and gastric precancerous lesions

  **Risk factors**        **NAG**            **AG**   **IM**                                                 
  ----------------------- ------------------ -------- ------------------- ------- ------------------ ------- --
  Age                     1.09 (0.99-1.03)   0.315    0.90 (0.88-1.01)    0.412   1.01 (0.99-1.02)   0.313   
  BMI                     1.01 (0.93-1.11)   0.421    0.89 (0.78-1.32)    0.587   1.11 (0.98-1.24)   0.134   
  Gender                  Female             \-                           \-                         \-      
  Male                    1.52 (0.79-2.14)   0.156    0.91 (0.42-1.83)    0.792   1.30 (0.88-1.91)   0.199   
  High salt               No                 \-                           \-                         \-      
  Yes                     2.58 (1.21-4.88)   0.011    0.59 (0.24-1.77)    0.315   1.01 (0.55-1.41)   0.699   
  *H. pylori* infection   No                 \-                           \-                         \-      
  Yes                     0.59 (0.37-1.08)   0.141    0.39 (0.65-0.99)    0.041   0.90 (0.77-1.31)   0.555   
  Smoking                 No                 \-                           \-                         \-      
  Yes                     2.15 (1.19-4.44)   0.015    1.11 (0.77-2.10)    0.515   1.97 (1.40-2.58)   0.005   
  Drinking                No                 \-                           \-                         \-      
  Yes                     1.00 (0.99-1.39)   0.057    0.731 (0.49-1.19)   0.161   0.95 (0.89-1.33)   0.668   
  Region                  South              \-                           \-                         \-      
  Middle                  0.33 (0.28-0.51)   0.009    0.71 (0.46-1.99)    0.669   2.95 (1.45-4.33)   0.007   
  North                   0.55 (0.40-1.01)   0.053    0.33 (0.21-0.83)    0.010   1.41 (0.89-2.01)   0.313   

BMI: Body mass index; *H. pylori*: Helicobacter pylori; NAG: Non-atrophic gastritis; AG: Atrophic gastritis; IM: Intestinal metaplasia.

Association of IL-21 gene polymorphisms and gastric precancerous lesions
------------------------------------------------------------------------

The genotype distributions of each group were consistent with Hardy-Weinberg equilibrium (*P* \> 0.05) (Table [4](#T4){ref-type="table"}). In univariate analyses, differences in the distribution frequency of rs907715 genotypes CC and C between cases and controls were statistically significant (OR = 1.77, 95%CI: 1.19-2.63, *P* = 0.005; OR = 1.43, 95%CI: 1.02-2.01, *P =* 0.039, respectively). Results were similar after adjusting for confounding factors (OR = 1.59, 95%CI: 1.06-2.38, *P* = 0.013; OR = 1.28, 95%CI: 1.01-2.22, *P =* 0.044, respectively). Results were also similar for IM when examined separately (OR = 1.92, 95%CI: 1.24-2.98, *P =* 0.004; OR = 1.53, 95%CI: 1.04-2.24, *P =* 0.028, respectively). The distribution frequencies of genotype CC and C were not statistically different between cases and controls in all models.

###### 

Comparison of the genotype distribution of the *IL-21* gene polymorphisms in gastric precancerous lesions

  **SNPs set**   **Geno-type**   **Control (*n* = 290, %)**   **NAG (*n* = 116, %)**   **AG (*n* = 106, %)**   **IM (*n* = 366, %)**   **OR~1~**   ***P*~1~ value**   **OR~2~**   ***P*~2~ value**   **OR~3~**   ***P*~3~ value**   **OR~4~**   ***P*~4~ value**   **OR~5~**   ***P*~5~ value**
  -------------- --------------- ---------------------------- ------------------------ ----------------------- ----------------------- ----------- ------------------ ----------- ------------------ ----------- ------------------ ----------- ------------------ ----------- ------------------
  rs907715       TT              70 (24.1)                    25 (21.6)                19 (17.9)               63 (17.2)               \-                             \-                             \-                             \-                             \-          
  CT             143 (49.3)      53 (45.7)                    50 (47.2)                170 (46.5)              1.04 (0.60-1.81)        0.896       1.29 (0.71-2.35)   0.408       1.32 (0.88-1.98)   0.179       1.25 (0.87-1.80)   0.230       1.13 (0.62-1.74)   0.439       
  CC             77 (26.6)       38 (32.7)                    37 (34.9)                133 (36.3)              1.38 (0.76-2.52)        0.290       1.77 (0.93-3.36)   0.079       1.92 (1.24-2.98)   0.004       1.77 (1.19-2.63)   0.005       1.59 (1.06-2.38)   0.013       
  C              220 (75.9)      91 (78.4)                    87 (82.1)                303 (82.8)              1.16 (0.69-1.94)        0.578       1.46 (0.83-2.56)   0.190       1.53 (1.04-2.24)   0.028       1.43 (1.02-2.01)   0.039       1.28 (1.01-2.22)   0.044       
  rs12508721     TT              39 (13.4)                    14 (12.1)                18 (17.0)               54 (14.8)               \-                             \-                             \-                             \-                             \-          
  CT             151 (52.1)      57 (49.1)                    55 (51.9)                178 (48.6)              1.05 (0.53-2.08)        0.885       0.79 (0.42-1.50)   0.467       0.85 (0.54-1.36)   0.498       0.87 (0.57-1.33)   0.525       0.82 (0.55-1.28)   0.618       
  CC             100 (34.5)      45 (38.8)                    33 (31.1)                134 (36.6)              1.25 (0.62-2.54)        0.529       0.72 (0.36-1.42)   0.335       0.97 (0.60-1.57)   0.895       0.96 (0.62-1.50)   0.863       0.88 (0.59-1.33)   0.879       
  C              251 (86.6)      102 (87.9)                   88 (83.0)                312 (85.2)              1.13 (0.59-2.17)        0.709       0.76 (0.41-1.40)   0.375       0.90 (0.58-1.40)   0.634       0.91 (0.60-1.36)   0.639       0.83 (0.49-1.19)   0.801       
  rs2221903      TT              231 (79.7)                   90 (77.6)                83 (78.3)               271 (74.0)              \-                             \-                             \-                             \-                             \-          
  CT             52 (17.9)       24 (20.7)                    21 (19.8)                80 (21.9)               1.19 (0.69-2.04)        0.539       1.12 (0.64-1.98)   0.685       1.31 (0.89-1.94)   0.173       1.25 (0.87-1.79)   0.223       1.08 (0.53-1.55)   0.459       
  CC             7 (2.4)         2 (1.7)                      2 (1.9)                  15 (4.1)                0.73 (0.15-3.60)        0.701       0.80 (0.16-3.91)   0.777       1.83 (0.73-4.56)   0.190       1.41 (0.59-3.41)   0.441       1.19 (0.41-2.87)   0.503       
  C              59 (20.3)       26 (22.4)                    23 (21.7)                95 (26.0)               1.13 (0.67-1.91)        0.643       1.09 (0.63-1.87)   0.769       1.37 (0.95-1.99)   0.092       1.27 (0.90-1.79)   0.171       1.08 (0.81-1.48)   0.311       

OR~1~: NAG cases compared with controls; OR~2~: AG cases compared with controls; OR~3~: IM cases compared with controls; OR~4~: Total gastric precancerous lesions cases compared with controls; OR~5~: Adjusted by age, gender, BMI, drinking status, smoking status, daily salt intake and region. SNPs: Single nucleotide polymorphisms; NAG: Non-atrophic gastritis; AG: Atrophic gastritis; IM: Intestinal metaplasia.

Analyses of rs907715 mRNA expression in intestinal epithelium tissue from six subjects with IM showed significant differences between CC genotype and TT genotype (*P* \< 0.001), CC genotype and CT genotype (*P* \< 0.01) (Figure [2](#F2){ref-type="fig"}). Similarly, rs907715 mRNA expression levels in six NAG tissues and six atrophic gastritis tissues were conducted. For NAG tissues, the expression level of rs907715 CC genotype was significantly different from that among the rs907715 CT genotype (*P* \< 0.05) and TT genotype (*P* \< 0.01) (Figure [3](#F3){ref-type="fig"}); for atrophic gastritis tissues, the expression level showed significant difference between rs907715 CC genotype and TT genotype (*P* \< 0.05) (Figure [4](#F4){ref-type="fig"}).

![Interleukin-21 mRNA expression level in six intestinal epithelium tissues among three rs907715 genotypes.](WJGO-12-289-g002){#F2}

![Interleukin-21 mRNA expression level in six non-atrophic gastritis tissues among three rs907715 genotypes.](WJGO-12-289-g003){#F3}

![Interleukin-21 mRNA expression level in six atrophic gastritis tissues among three rs907715 genotypes.](WJGO-12-289-g004){#F4}

Haplotype Analyses
------------------

The results showed that the TC haplotype (rs907715 and rs12508721) was significantly associated with AG and IM (OR = 3.91, *P =* 0.003; OR = 2.02, *P =* 0.004, respectively), and it appeared to be a risk haplotype; the TT haplotype (rs2221903 and rs907715) was significantly associated with IM (OR = 1.44, *P =* 0.023) and it appeared to be a risk haplotype (Table [5](#T5){ref-type="table"}).

###### 

Haplotype analysis of polymorphisms in patients and controls

  **SNPs**                **Haplo-type**   **Control (*n* = 290, %)**   **NAG (*n* = 116, %)**   **AG (*n* = 106, %)**   **IM (*n* = 366, %)**   ***χ*^2^~-1~**   ***P*~1~ value**   **OR~1~**          ***χ*^2^~-2~**   ***P*~2~ value**    **OR~2~**          ***χ*^2^~-3~**   ***P*~3~ value**   **OR~3~**
  ----------------------- ---------------- ---------------------------- ------------------------ ----------------------- ----------------------- ---------------- ------------------ ------------------ ---------------- ------------------- ------------------ ---------------- ------------------ ------------------
  rs907715\| rs12508721   CC               0.496                        0.543                    0.575                   0.571                   0.713            0.397              1.20 (0.78-1.86)   1.936            0.164               1.37 (0.88-2.15)   3.612            0.057              1.35 (1.00-1.84)
  CT                      0.066            0.060                        0.057                    0.071                   0.037                   0.847            1.09 (0.45-2.67)   0.104              0.747            1.17 (0.45-3.01)    0.077              0.781            0.92 (0.50-1.69)   
  TC                      0.163            0.138                        0.047                    0.087                   0.368                   0.544            1.21 (0.66-2.23)   8.984              0.003            3.91 (1.51-10.11)   8.509              0.004            2.02 (1.25-3.26)   
  TT                      0.275            0.259                        0.321                    0.271                   0.125                   0.724            1.09 (0.67-1.78)   0.763              0.382            0.81 (0.50-1.31)    0.024              0.878            1.03 (0.73-1.45)   
  rs2221903\| rs907715    CC               0.128                        0129                     0.123                   0.158                   0.002            0.963              0.99 (0.52-1.87)   0.017            0.896               1.05 (0.53-2.06)   1.264            0.264              0.78 (0.50-1.21)
  CT                      0.006            0.026                        0.019                    0.014                   2.450                   0.118            0.26 (0.04-1.59)   1.113              0.292            0.36 (0.05-2.60)    0.701              0.404            0.50 (0.10-2.60)   
  TC                      0.434            0.474                        0.509                    0.484                   0.527                   0.468            0.85 (0.55-1.31)   1.759              0.185            0.74 (0.47-1.16)    1.571              0.210            0.82 (0.60-1.12)   
  TT                      0.432            0.371                        0.349                    0.344                   1.244                   0.265            1.29 (0.83-2.00)   2.158              0.142            1.41 (0.89-2.24)    5.157              0.023            1.44 (1.05-1.98)   

Haplotype of rs907715(C/T), rs2221903 (T/C) and rs12508721(C/T). OR~1~: NAG cases compared with controls; OR~2~: AG cases compared with controls; OR~3~: IM cases compared with controls. SNPs: Single nucleotide polymorphisms; NAG: Non-atrophic gastritis; AG: Atrophic gastritis; IM: Intestinal metaplasia.

DISCUSSION
==========

Our results suggested that rs907715 genotypes CC and C confer increased susceptibility to IM and total gastric precancerous lesions, whereas no association was found for rs2221903 or rs12508721. Because we are not aware of any previous study that directly addressed these associations, our findings should be interpreted cautiously.

Regarding rs907715, Liu et al\[[@B30]\], for example, reported that genotype AA and A allele of rs907715 were associated with the decreased susceptibility to non-small cell lung cancer. Xiao et al\[[@B31]\] revealed that the G allele of rs907715 increased the susceptibility to Graves' disease. Moreover, a case-control study found that serum *IL-21* levels in HBV patients with rs907715 genotype AA were lower than those in patients with genotype AG/GG; this genotype was independently related to sustained virological response\[[@B40]\]. A meta-analysis showed that the genotype distribution of *IL-21* rs907715 was significantly different between systemic lupus erythematosus patients and healthy controls in all genetic models\[[@B26]\]. All of these findings suggest that rs907715 of *IL-21* may to some extent exert effects on antitumor, antiviral and/or inflammatory processes. However, other studies have shown no association between rs907715 and thyroid cancer\[[@B31]\] and breast cancer\[[@B32]\]. Hence, the associations we observed in our study should be addressed in future studies.

The *IL-21* gene is located on human chromosome 4q26-27 and plays an important role in anti-tumor immunopathology\[[@B41]\]. Previous studies have found that *IL-21* is overexpressed in *H. pylori*-infected gastric mucosa\[[@B42]\], and is correlated with the occurrence and development of gastritis\[[@B34],[@B35]\]. Moreover, studies have found that the concentration of *IL-21* is increased in both tissue and serum of GC patients\[[@B43],[@B44]\]. Thus, IL-21 may play a role in the development and progression of GC and gastritis-related diseases. Previous evidence has shown that SNP rs907715 is associated with increased *IL-21* transcription and expression\[[@B40],[@B45]\]. The rs907715, locating in the third intron of *IL-21* gene, may be a surrogate marker for mutations with functional consequences\[[@B25]\]. SNPs including rs907715 may be in linkage disequilibrium with a variant correlated with mRNA translation, thereafter may lead to the change of protein expression\[[@B27]\]. Therefore, SNP rs907715 of *IL-21* gene may alter the mRNA expression levels and regulate the function of *IL-21*. This suggested that rs907715 may be related to the risk of gastric precancerous lesions by influencing the activities of *IL-21*.

The data regarding TC haplotype frequency (rs907715 and rs12508721) in AG and IM patients compared to controls showed that this haplotype may be a risk for gastric precancerous lesions. Similarly, the TT haplotype frequency (rs2221903 and rs907715) in IM patient compared to controls showed that this haplotype may be a risk for IM. This result suggested that the two haplotypes, according to the *IL-21* polymorphisms, might be the important genetic factors for susceptibility to gastric precancerous lesions.

The present study selected subjects in three cities from north to south in Shaanxi province, which enhanced the power of population representation and made our results more credible. However, this study also has several limitations. First, all cases and controls were selected from participants experiencing upper gastrointestinal symptoms, which may cause a potential selection bias and increase the positive results of the study. Second, controls were screened from subjects with non-*H. pylori* infection and non-precancerous lesions to represent the general population, this led to a mismatched number of cases and controls, which may weaken the testing effectiveness. Third, this study was a case-control study and unable to draw a causal relationship.

In conclusion, our study found that SNP rs907715 was associated with gastric precancerous lesions, and the TC haplotype (rs907715 and rs12508721) and TT haplotype (rs2221903 and rs907715) increased the risk of gastric precancerous lesions, which may help clarify the etiology of GC. Further studies are required to elucidate the roles of rs907715 in development of gastric precancerous lesions at a molecular level, which may provide new targets for therapeutic interventions.

ARTICLE HIGHLIGHTS
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Research background
-------------------

Previous studies have found that interleukin-21 (*IL-21*) may be associated with the risk of gastric precancerous lesions, and single nucleotide (SNPs) of the *IL-21* gene are associated with various diseases or cancer. Clarifying the possible role of *IL-21* SNPs (rs907715, rs2221903 and rs12508721) in gastric precancerous lesions is of great significance in preventing the development of gastric cancer.

Research motivation
-------------------

However, no studies have examined the possible role of *IL-21* SNPs (rs907715, rs2221903 and rs12508721) in gastric precancerous lesions.

Research objectives
-------------------

Therefore, the present study explored the associations between SNPs of *IL-21* (rs907715, rs2221903 and rs12508721) and risk of gastric precancerous lesions in a north western Chinese population, which may help clarify the etiology of gastric cancer and provide new targets for therapeutic interventions.

Research methods
----------------

Gastric precancerous lesions were confirmed by endoscopic examination and categorized as non-atrophic gastritis, atrophic gastritis, and intestinal metaplasia. Three SNPs of *IL-21* (rs907715, rs2221903 and rs12508721) were genotyped using polymerase chain reaction--ligase detection reaction in 588 cases and 290 healthy controls. Descriptive statistic and logistic regression were used for data analyses.

Research results
----------------

We found an association between *IL-21* rs907715 polymorphism and gastric precancerous lesions. *IL-21* rs907715 genotype CC and C frequencies in patients with gastric precancerous lesions were higher than in controls. SNP rs907715 increased in CC and C genotypes were associated with intestinal metaplasia patients when examined separately. However, the exact role of rs907715 in development of gastric precancerous lesions at a molecular level remains to be studied.

Research conclusions
--------------------

In conclusion, our findings indicate that SNP rs907715 of *IL-21* gene is associated with gastric precancerous lesions.

Research perspectives
---------------------

If confirmed by other studies, the results of our study suggest that *IL-21* rs907715 polymorphisms may shed light on the etiology of precancerous lesions.
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